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Abstract
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is common in populations living in malaria
endemic areas. G6PD genotype and phenotype were determined for malaria patients enrolled in the
chlorproguanil-dapsone-artesunate (CDA) phase III clinical trial programme.
Methods: Study participants, aged > 1 year, with microscopically confirmed uncomplicated Plasmodium falciparum
malaria, and haemoglobin ≥ 70 g/L or haematocrit ≥ 25%, were recruited into two clinical trials conducted in six
African countries (Burkina Faso, Ghana, Kenya, Nigeria, Tanzania, Mali). G6PD genotype of the three most common
African forms, G6PD*B, G6PD*A (A376G), and G6PD*A- (G202A, A542T, G680T and T968C), were determined and
used for frequency estimation. G6PD phenotype was assessed qualitatively using the NADPH fluorescence test.
Exploratory analyses investigated the effect of G6PD status on baseline haemoglobin concentration, temperature,
asexual parasitaemia and anti-malarial efficacy after treatment with CDA 2/2.5/4 mg/kg or chlorproguanil-dapsone
2/2.5 mg/kg (both given once daily for three days) or six-dose artemether-lumefantrine.
Results: Of 2264 malaria patients enrolled, 2045 had G6PD genotype available and comprised the primary analysis
population (1018 males, 1027 females). G6PD deficiency prevalence was 9.0% (184/2045; 7.2% [N = 147] male
hemizygous plus 1.8% [N = 37] female homozygous), 13.3% (273/2045) of patients were heterozygous females,
77.7% (1588/2045) were G6PD normal. All deficient G6PD*A- genotypes were A376G/G202A. G6PD phenotype was
available for 64.5% (1319/2045) of patients: 10.2% (134/1319) were G6PD deficient, 9.6% (127/1319) intermediate,
and 80.2% (1058/1319) normal. Phenotype test specificity in detecting hemizygous males was 70.7% (70/99) and
48.0% (12/25) for homozygous females. Logistic regression found no significant effect of G6PD genotype on
adjusted mean baseline haemoglobin (p = 0.154), adjusted mean baseline temperature (p = 0.9617), or adjusted
log mean baseline parasitaemia (p = 0.365). There was no effect of G6PD genotype (p = 0.490) or phenotype (p =
0.391) on the rate of malaria recrudescence, or reinfection (p = 0.134 and p = 0.354, respectively).
Conclusions: G6PD deficiency is common in African patients with malaria and until a reliable and simple G6PD
test is available, the use of 8-aminoquinolines will remain problematic. G6PD status did not impact baseline
haemoglobin, parasitaemia or temperature or the outcomes of anti-malarial therapy.
Trial registration: Clinicaltrials.gov: NCT00344006 and NCT00371735.
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Glucose-6-phosphate dehydrogenase (G6PD) is an
enzyme in the pentose phosphate pathway (PPP) that
plays an important role in protecting cells from oxida-
tive damage by producing NADPH and reduced glu-
tathione. In the erythrocyte, which lacks a nucleus,
mitochondria and other organelles, PPP is the only bio-
chemical pathway for generating reducing capacity [1,2].
The G6PD gene is highly polymorphic with almost 400
reported variants, conferring varying levels of enzyme
activity [2]. G6PD is X-linked, and so deficient variants
are expressed more commonly in males than in females.
Worldwide, an estimated 400 million people are G6PD
deficient with the distribution corresponding to areas in
which malaria is, or has been, prevalent. This has led to
speculation that malaria has been the selection pressure
that has favoured the maintenance of this potentially
deleterious trait. There is some evidence that hemizy-
gous males may be protected against severe malaria
[1,3-5].
Although there are over 400 G6PD variants worldwide,
in sub-Saharan Africa three variants occur with poly-
morphic frequencies (> 0.1%); G6PD*B, G6PD*A and
G6PD*A-. G6PD*B is the wild type and the most common
variant in Africa and worldwide. G6PD*A has a single
A®G substitution at nucleotide number 376, though is a
normal variant with about 90% of the G6PD*B enzyme
activity [6]. G6PD*A- is a deficient variant with about
8-20% of the wild type enzyme activity and, in addition to
the A376G mutation that describes the G6PD*A variant,
most commonly also involves a G®A substitution at
nucleotide 202 [7]. However, G6PD*A- variants with sub-
stitutions at 542 G®T, 680 G®T or 968 T®C have also
been identified in Africa [3,8].
Individuals with G6PD*A- are normally asymptomatic
[1]. However, erythrocyte exposure to oxidative stress
causes haemoglobin denaturation, ultimately resulting in
haemolysis. Haemolytic anaemia in G6PD-deficient indi-
viduals can be triggered by a range of oxidative agents,
such as infections and certain foods and drugs, including
anti-malarials [9].
This study reports the frequency of G6PD genotypes
and phenotypes in malaria patients who participated in
two Phase III clinical trials of chlorproguanil-dapsone-
artesunate (CDA) [10,11]. The CDA clinical trial pro-
gramme was terminated because of an increased risk of
drug-related haemolysis with CDA in G6PD-deficient
compared with G6PD-normal malaria patients [10,11].
The haemolysis was almost certainly because of the dap-
sone component [10-13]. This paper also reports that
G6PD genotype did not influence baseline haemoglobin
concentrations, temperature and asexual parasitaemia or
the outcomes of anti-malarial efficacy.
Methods
The clinical data from the CDA trials have been pub-
lished separately and those reports include more com-
prehensive descriptions of the conduct of the individual
trials [10,11].
Ethics statement
This study was conducted in accordance with Good
Clinical Practices, applicable regulatory requirements,
and the Declaration of Helsinki. Approval was obtained
from each participating centre’s ethics committee or
institutional review board and the WHO Special Pro-
gramme for Research and Training in Tropical Diseases
(TDR). An Independent Data Monitoring Committee
(IDMC) was convened and planned to conduct two
interim safety analyses. The IDMC appointed an inde-
pendent end-point reviewer (blinded to treatment
assignment). Written or oral witnessed informed con-
sent was required from patients or their parent/guardian
plus assent from patients who were ≥ 12-18 years old.
Objectives
This study used genotyping and phenotyping to deter-
mine the frequency of G6PD deficiency in malaria
patients included in the CDA Phase III clinical trial pro-
gramme in Africa. Exploratory analyses investigated
whether baseline haemoglobin concentration, tempera-
ture and asexual parasitaemia were influenced by G6PD
genotype. The effect of G6PD status on anti-malarial
efficacy was also examined.
Participants
Patients were screened for inclusion into two clinical
trials. Study 005 compared CDA versus artemether-
lumefantrine (AL) in malaria patients aged > 1- < 14
years of age and was conducted between June 2006 and
August 2007 at 11 centres in five African countries:
Bobo-Dioulasso, Burkina Faso; Kintampo, Ghana;
Eldoret, Kilifi and Pingilikani, Kenya; Ibadan, Enugu, Jos
and Calabar, Nigeria; and Bagamoyo and Kiwangwa, Tan-
zania [11]. Study 006 compared CDA versus chlorpro-
guanil-dapsone (CPG-DDS) in patients > 1 year old and
was conducted between April 2006 to May 2007 at seven
health centres in four African countries: Ouagadougou,
Burkina Faso; Kumasi, Ghana; Doneguebougou and
Banambani, Mali; and Ile-Ife, Jos and Lagos, Nigeria [10].
Across the two trials, eligible subjects included males
and females who met the following inclusion criteria:
acute uncomplicated microscopically verified Plasmodium
falciparum malaria (parasite count 2000 to 200,000 μL
-1);
fever at enrollment or history of fever; weight ≥ 7.5 kg;
haemoglobin ≥ 70 g/L or haematocrit ≥ 25%; willingness
to comply with study procedures.
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P. falciparum malaria; known G6PD deficiency, methae-
moglobin reductase deficiency, haemoglobin M/E (i.e.
increased risk of methaemoglobinaemia), or porphyria;
neonatal hyperbilirubinaemia; received potentially hae-
molytic concomitant medication; concomitant infection
(including Plasmodium vivax, Plasmodium ovale or Plas-
modium malariae); any underlying disease that could
compromise malaria diagnosis or the anti-malarial effi-
cacy assessment; known hypersensitivity/allergy to study
treatments or biguanides, sulphones, sulphonamides, or
artemisinin derivatives; malnutrition; received recent
anti-malarial therapy that may affect the efficacy evalua-
tion or any investigational drug within 30 days or five
half-lives (whichever longer); previously participated in
the study. A negative pregnancy test was required from
women of child-bearing age; breastfeeding mothers were
excluded.
Procedures
During screening, all patients provided a full medical his-
tory and underwent a comprehensive clinical examina-
tion. Drug treatments were CDA 2/2.5/4 mg/kg, CPG-
DDS 2/2.5 mg/kg (both GlaxoSmithKline, Greenford,
UK) given once daily for three days (Days 0, 1, 2) or six-
dose AL (Novartis Pharma AG, Basel, Switzerland). Ran-
domization was 2:1 CDA versus the comparator. Details
of patient assessments are given in the clinical reports of
these trials [10,11]. Patients remained hospitalized
between Days 0 to 3, with follow up on Days 7, 14, and 28
in both studies, and follow up also at Day 42 in the CDA
versus AL study (005); with a home visit from a fieldwor-
ker on Days 4, 5, and 6.
Blinding
G6PD genotype and phenotype were determined by labora-
tory staff blinded to treatment. Clinical investigators were
blinded to drug treatment and G6PD status was not avail-
able to clinical investigators until after the trial was
complete.
Parasite assessment
>Asexual parasite and gametocyte counts were deter-
mined by examination of duplicate Giemsa-stained thick
blood slides (10 μL thumb prick) using WHO (2003)
methods [14]. Thick blood slides were examined by two
microscopists blinded to treatment; a third microscopist
read the slides in case of a discrepancy. To differentiate
recrudescence from reinfection, two drops of blood col-
lected at enrollment and subsequent date of parasite
detection were stored on filter paper for polymerase
chain reaction (PCR) analysis of parasite genotype using
msp-1, msp-2 and glurp [15,16].
G6PD genotyping
G6PD genotype analysis was performed at two labora-
tories: Walter Reed Project/Kenya Medical Research Insti-
tute, Kisumu, Kenya and Shoklo Malaria Research Unit,
Mae Sot, Thailand. After patient randomization, but
before the first dose of study therapy, a 10 μL blood sam-
ple was collected (thumb prick) onto pre-printed filter
paper. The G6PD genotyping protocol was based on pub-
lished methods [17-19]. Specific forward primers and
reverse primers were used for PCR amplification of a sec-
tion of G6PD gene containing G6PD*B (wild type), the
common African mutation G6PD*A (A376G) and the
other deficient variant G6PD*A- (G202A, A542T, G680T
and T968C). Amplicons were subsequently analysed by
restriction fragment length polymorphism (RFLP) and
genotypes scored after agarose gel electrophoresis. DNA
was extracted using standard methods. PCR was per-
formed using 0.75 U/μL Taq Polymerase, 1.5 mM MgCl2,
200 μM dNTP (mix 10 mM), 2.5 μM of each primer, 10%
PCR buffer, and 2.0 μL of DNA. All restriction endonu-
cleases were sourced from New England Biolabs (Ipswich,
MA, USA) and used at optimal temperature and digestion
period. Genomic DNA was first amplified using primers
for A376G, 5’-CCCAGGCCACCCCAGAGGAGA-3’ (for-
ward) and 5’-CGGCCCCGGACACGCTCATAG-3’
(reverse). Thermocycling was performed at 94°C for 10
min, then 30 cycles at 94°C for 45 sec, 58°C (annealing
temperature) for 45 sec, and 72°C for 45 sec, with a final
extension at 72°C for 7 min. Amplification products were
recovered and PCR fragments incubated at 37°C for 16 h
with FokI for identification of the A376G mutation
(G6PD*A). All samples positive for A376G were then sub-
jected to PCR amplification using: G202A, 5’-CCAC-
CACTGCCCCTGTGACCT-3’ (forward) and 5’-GGCC
CTGACACCACCCACCTT-3’ (reverse) with annealing at
65°C; G542T, 5’-AGGAGATGTGGTTGGACATCCGG-3’
(forward) and 5’-ACTCCCCGAAGAGGGGT-3’ (reverse)
with annealing at 67°C; G680T, 5’-ACATGTGGCC
CCTGCACCAC-3’ (forward) and 5’-GTGACTGGCT
CTGCCACCCTG-3’ (reverse) with annealing at 69°C; and
T968C 5’-TCCCTGCACCCCAACTCAAC-3’ (forward)
and 5’-CCAGTTCTGCCTTGCTGGGC-3’ (reverse) with
annealing at 65°C. Amplicons were then incubated at 37°C
for 16 h with NlaIII for identification of the G202A muta-
tion, AccIII for G542T, BstNI for G680T, and NciI for the
T968C mutation. Quality control was maintained by com-
paring results from the two testing laboratories with
discrepant results reanalysed.
G6PD phenotyping
Pre-dose venous blood samples (2 mL) were collected
for G6PD phenotyping, refrigerated to 4°C and trans-
ported within seven days to a central laboratory (Synexa,
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cial NADPH fluorescence test (Trinity Biotech, Wick-
low, Ireland). This was a qualitative test designed to
distinguish grossly G6PD-deficient samples from those
with intermediate/normal enzyme activity. The reaction
mixture containing glucose-6-phosphate+NADP (not
fluorescent) and spots were made on the filter paper at
the beginning (zero-time) and 5, 10, and 20 min after
blood incubation with reagentm i x t u r e .T h es p o t sw e r e
visually inspected under long-wavelength (320-420 nm)
ultraviolet light. The observed rate of appearance of
bright fluorescence is proportional to the blood G6PDH
activity; normal samples fluoresce brightly, whereas defi-
cient samples show little or no fluorescence [20].
Efficacy outcomes
Day-28 parasite recrudescence and reinfection rates, differ-
entiated using PCR genotyping as described above, were
used to evaluate whether G6PD genotype or phenotype
had an effect on anti-malarial efficacy.
Statistical methods
Descriptive statistics were used to report demographic and
clinical characteristics for patients with G6PD genotype.
G6PD genotype and phenotype was presented by country
and centre.
All statistical analyses were performed post-hoc. There
was no formal sample size calculation for the analyses
reported in this paper. Sample size was calculated for clini-
cal endpoints as reported previously [10,11]. Analysis of
conformity with the Hardy-Weinberg equilibrium for
female gene frequencies was analysed by centre, country
and overall. Expected female gene frequencies were calcu-
lated based on male genotype prevalence (A-, A and B)
and compared with observed values using Chi-squared.
A logistic model was developed to investigate the
effect of G6PD genotype on the following baseline vari-
ables: haemoglobin concentration, temperature, and
asexual parasite count.
The effect of G6PD genotype was evaluated using three
categories: normal; heterozygous; or deficient (hemizygous
males plus homozygous females). The effect of G6PD gen-
otype on baseline haemoglobin concentration was mod-
elled with terms for age category (< 5, ≥ 5- < 15, ≥ 15
years), weight, centre, sex, temperature and parasitaemia
category (four quartiles). The model for the effect of G6PD
genotype on temperature had terms for age category,
weight, centre, sex, haemoglobin concentration and parasi-
taemia category. To investigate the effect of G6PD geno-
type on parasitaemia, parasite densities were initially log
transformed with model terms for age category, weight,
centre, sex, haemoglobin concentration and temperature.
A logistic model was developed to investigate the effect
of G6PD genotype (normal, heterozygous, deficient) on
anti-malarial efficacy (recrudescence and reinfection
rates) with terms for: anti-malarial treatment, study
(CDA vs. AL; CDA vs. CPG-DDS), age category, weight,
centre, sex, and parasitaemia category. The same model
was used to investigate the effect of G6PD phenotype
(normal, intermediate, deficient) on anti-malarial efficacy.
The models were used to calculate adjusted mean values
for the variable under investigation and a p value calcu-
lated to test any significant effect of model terms using
analysis of variance. G6PD genotype was further analysed
to compare G6PD normal with heterozygous and G6PD
normal with G6PD deficient; 95% confidence intervals
were calculated and p values generated using analysis of
variance.
Results
Patients
A summary of the patient population that was screened,
randomized and analysed for G6PD status is shown in
Figure 1. Across the two studies 2264 malaria patients
were enrolled. G6PD genotype and phenotype was avail-
able for 2045 and 1319 subjects, respectively, and this
comprised the primary analysis population.
G6PD deficiency prevalence
Table 1 shows G6PD gene frequencies for males (N =
1018) and females (N = 1027) by country and trial centre.
T h e r ew e r en oG 6 P Dd a t af r o mL a g o s ,N i g e r i a .O ft h e
2045 patients, 77.7% (1588/2045) were G6PD normal,
13.3% (273/2045) were female heterozygous and 9.0%
(184/2045) were G6PD deficient, i.e. 7.2% (147/2045)
male hemizygous plus 1.8% (37/2045) female homozy-
gous. All deficient G6PD*A- genotypes were A376G/
G202A; there were no instances of A542T, G680T or
T968C. Hardy-Weinberg equilibrium was demonstrated
for four of 14 centres: Ouagadougou (Burkina Faso), Kilifi
(Kenya), Banambani (Mali) and Kiwangwa (Tanzania)
(Table 1).
G6PD phenotype results are shown in Table 2. Pheno-
type was available for 64.5% (1319/2045) of patients.
Overall, 10.2% (134/1319) of patients were phenotypically
G6PD deficient, 9.6% (127/1319) intermediate, and 80.2%
(1058/1319) normal (Table 2). Of the G6PD*A- hemizy-
gous males that had phenotype data available, 70/99
(70.7%) were phenotypically G6PD deficient and 29/99
(29.3%) had intermediate/normal phenotype (Table 3).
Of the G6PD*A- homozygous females, 12/25 (48.0%) had
deficient phenotype and 13/25 (52.0%) had normal/inter-
mediate phenotype (Table 3). Likewise, 39/1021 (3.1%)
patients of normal G6PD genotype (males A or B,
females AA, AB or BB) were classified as G6PD deficient
and 68/1021 (6.7%) as intermediate, illustrating the fluid-
ity of G6PD measurements. As expected, female hetero-
zygous displayed a wide range of G6PD activity.
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Baseline demographic and clinical characteristics of the
study participants are summarized in Table 4. Figure 2
shows baseline haemoglobin categorized by G6PD geno-
type and age. Logistic regression found no significant
effect of G6PD genotype on adjusted mean baseline hae-
moglobin (p = 0.154). Comparison between G6PD
normal and heterozygous (p = 0.693), or between G6PD
normal and deficient genotype (p = 0.0559) showed no
difference in adjusted mean baseline haemoglobin. Note
that this population was selected to have a baseline hae-
moglobin ≥ 70 g/L and this may have biased the results.
Figures 3 and 4 show baseline temperature and parasi-
taemia categorized by G6PD genotype, respectively.
17,534 subjects screened:
758 (4.3) Burkina Faso
882 (5.0) Ghana
5425 (30.9) Kenya
318 (1.8) Mali
7195 (41.0) Nigeria
2956 (16.9) Tanzania
2264 randomised:
365 (16.1) Burkina Faso
256 (11.3) Ghana
300 (13.3) Kenya
310 (13.7) Mali
701 (31.0) Nigeria
332 (14.7) Tanzania
           Genotype population
2045 (90.3) with G6PD genotype:
357 (17.5) Burkina Faso
236 (11.5) Ghana
293 (14.3) Kenya
308 (15.1) Mali
547 (26.7) Nigeria
304 (14.9) Tanzania
           Phenotype population
1319 (58.3) with G6PD genotype and
phenotype:
343 (26.0) Burkina Faso
138 (10.5) Ghana
219 (16.6) Kenya
294 (22.3) Mali
164 (12.4) Nigeria
161 (12.2) Tanzania
1372 randomised
to 005 study
914 randomised to
CDA
1201 with G6PD
genotype in 005 study
844 with G6PD
genotype in 006 study
590 with G6PD
phenotype in 005 study
729 with G6PD
phenotype in 006 study
458 randomised to
AL
292 randomised to
CPG-DDS
600 randomised to
CDA
800 patients in
CDA group
401 patients in
AL group
282 patients in
CPG-DDS group
562 patients in
CDA group
392 patients in
CDA group
198 patients in AL
group
All values are shown as n (%).
243 patients in
CPG-DDS group
486 patients in
CDA group
892 randomised to
006 study
Figure 1 Trial profile and patient population.
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Page 5 of 14Table 1 Frequency of G6PD genotypes in malaria patients from 17 centres in six African countries
Country Centre Male N A- A B Female N A-A- AA- BA- AA BB BA HW* p
BF Bobo-Dioulasso 1 0 1 (100) 0 4 0 0 2 (50.0) 0 1 (25.0) 1 (25.0) NC
Ouagadougou 174 27 (15.5) 48 (27.6) 99 (56.9) 178 6 (3.4) 15 (8.4) 33 (18.5) 18 (10.1) 54 (30.3) 52 (29.2) 0.742
Total 175 27 (15.4) 49 (28.0) 99 (56.6) 182 6 (3.3) 15 (8.2) 35 (19.2) 18 (9.9) 55 (30.2) 53 (29.1) 0.771
Ghana Kintampo 92 16 (17.4) 52 (56.5) 24 (26.1) 87 8 (9.2) 10 (11.5) 21 (24.1) 9 (10.3) 22 (25.3) 17 (19.5) 0.003
Kumasi 19 2 (10.5) 4 (21.1) 13 (68.4) 38 1 (2.6) 1 (2.6) 5 (13.2) 6 (15.8) 13 (34.2) 12 (31.6) 0.019
Total 111 18 (16.2) 28 (25.2) 65 (58.6) 125 9 (7.2) 11 (8.8) 26 (20.8) 15 (12.0) 35 (28.0) 29 (23.2) 0.001
Kenya Eldoret 77 15 (19.5) 22 (28.6) 40 (51.9) 72 2 (2.8) 2 (2.8) 10 (13.9) 1 (1.4) 42 (58.3) 15 (20.8) < 0.001
Kilifi 41 8 (19.5) 10 (24.4) 23 (56.1) 33 2 (6.1) 3 (9.1) 8 (24.2) 1 (3.0) 10 (30.3) 9 (27.3) 0.961
Pingilikani 39 5 (12.8) 7 (17.9) 27 (69.2) 31 1 (3.2) 7 (22.6) 5 (16.1) 1 (3.2) 11 (35.5) 6 (19.4) < 0.001
Total 157 28 (17.8) 39 (24.8) 90 (57.3) 136 5 (3.7) 12 (8.8) 23 (16.9) 3 (2.2) 63 (46.3) 30 (22.1) 0.016
Mali Doneguebougou 114 10 (8.8) 41 (36.0) 63 (55.3) 102 2 (2.0) 4 (3.9) 20 (19.6) 14 (13.7) 39 (38.2) 23 (22.5) < 0.001
Banambani 48 7 (14.6) 13 (27.1) 28 (58.3) 44 1 (2.3) 1 (2.3) 7 (15.9) 2 (4.5) 23 (52.3) 10 (22.7) 0.176
Total 162 17 (10.5) 54 (33.3) 91 (56.2) 146 3 (2.1) 5 (3.4) 27 (18.5) 16 (11.0) 62 (42.5) 33 (22.6) < 0.001
Nigeria Calabar 76 11 (14.5) 11 (14.5) 54 (71.1) 69 0 7 (10.1) 13 (18.8) 5 (7.2) 33 (47.8) 11 (15.9) 0.005
Enugu 121 17 (14.1) 32 (26.4) 72 (59.5) 98 5 (5.1) 11 (11.2) 23 (23.5) 1 (1.0) 41 (41.8) 17 (17.3) 0.001
Ibadan 26 2 (7.7) 2 (7.7) 22 (84.6) 30 0 3 (10.0) 4 (13.3) 3 (10.0) 15 (50.0) 5 (16.7) < 0.001
Ile Ife 49 7 (14.3) 14 (28.6) 28 (57.1) 57 5 (8.8) 4 (7.0) 14 (24.6) 4 (7.0) 20 (35.1) 10 (17.5) 0.002
Jos 11 0 4 (36.4) 7 (63.6) 10 0 2 (20.0) 1 (10.0) 3 (30.0) 2 (20.0) 2 (20.0) NC
Total 283 37 (13.1) 63 (22.3) 183 (64.7) 264 10 (3.8) 27 (10.2) 55 (20.8) 16 (6.1) 111 (42.0) 45 (17.0) < 0.001
Tanzania Bagamoyo 19 4 (21.1) 4 (21.1) 11 (57.9) 23 0 0 0 5 (21.7) 13 (56.5) 5 (21.7) < 0.001
Kiwangwa 111 16 (14.4) 18 (16.2) 77 (69.4) 151 4 (2.6) 11 (7.3) 26 (17.2) 3 (2.0) 60 (39.7) 47 (31.1) 0.063
Total 130 20 (15.4) 22 (16.9) 88 (67.7) 174 4 (2.3) 11 (6.3) 26 (14.9) 8 (4.6) 73 (42.0) 52 (29.9) 0.094
Total 1018 147 (14.4) 283 (27.8) 588 (57.8) 1027 37 (3.6) 81 (7.9) 192 (18.7) 76 (7.4) 399 (38.8) 242 (23.5) < 0.001
Data shown as n (%) BF, Burkina Faso; NC, not calculated. G6PD genotype: male hemizygous = A-; male normal = A or B; female homozygous = A-/A-; female heterozygous = A/A- or B/A-; and female normal = A/A,
B/B or B/A.
*p values < 0.05 indicate significant differences from predicted G6PD gene frequencies in females based on male gene frequencies for A-, A and B alleles using the Hardy-Weinberg equation (Chi-squared).
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4Logistic regression showed no significant effect of G6PD
genotype on adjusted mean baseline temperature (p =
0.9617). Comparisons of adjusted mean baseline tem-
perature between G6PD normal and heterozygous (p =
0.784) or G6PD normal and deficient genotype (p =
0.969) found no significant differences. G6PD genotype
had no significant effect on adjusted log mean baseline
parasitaemia (p = 0.365). There was no difference in
adjusted log mean parasitaemia between G6PD normal
versus heterozygous (p = 0.181) or G6PD normal versus
deficient genotype (p = 0.693).
G6PD genotype and anti-malarial efficacy
Table 5 shows recrudescence and reinfection rates by
genotype and phenotype. There were 104/2045 (5.1%)
patients with parasite recrudescence during the CDA
clinical trials. Logistic modelling found no effect of
G6PD genotype (p = 0.490) or phenotype (p = 0.391) on
recrudescence rate. There was also no significant differ-
ence in recrudescence rate between normal and hetero-
zygous G6PD genotypes (odds ratio [OR] 0.7; 95%CI
0.4, 1.4; p = 0.315) or normal and deficient genotypes
(OR 1.2; 95%CI 0.6, 2.4; p = 0.561).
Reinfection with falciparum malaria occurred in 608/
2045 (29.7%) patients overall in the study. Based on the
r a wd a t a( T a b l e5 ) ,t h e r ew a sat r e n df o rl o w e rr e i n f e c -
tion rates in patients that had G6PD-deficient (26.6%) or
heterozygous genotypes (26.0%) versus normal genotype
(30.7%). Also, patients with a deficient phenotype had a
lower reinfection rate (26.7%) than those with a normal
Table 2 Frequency of G6PD phenotype by centre and country
Country Centre N* Deficient Intermediate Normal
BF Bobo-Dioulasso 0 0 0 0
Ouagadougou 343 29 (8.5) 37 (10.8) 277 (80.8)
Total 343 29 (8.5) 37 (10.8) 277 (80.8)
Ghana Kintampo 118 8 (6.8) 15 (12.7) 95 (80.5)
Kumasi 20 1 (5.0) 0 19 (95.0)
Total 138 9 (6.5) 15 (10.9) 114 (82.6)
Kenya Eldoret 90 15 (16.7) 4 (4.4)1 71 (78.9)
Kilifi 67 7 (10.4) 7 (10.4) 53 (79.1)
Pingilikani 62 4 (6.5) 3 (4.8) 55 (88.7)
Total 219 26 (11.9) 14 (6.4) 179 (81.7)
Mali Doneguebougou 205 17 (8.3) 20 (9.8) 168 (82.0)
Banambani 89 10 (11.2) 11 (12.4) 68 (76.4)
Total 294 27 (9.2) 31 (10.5) 236 (80.3)
Nigeria Calabar 21 5 (23.8) 2 (9.5) 14 (66.7)
Enugu 71 6 (8.5) 10 (14.1) 55 (77.5)
Ibadan 0 0 0 0
Ile Ife 72 7 (9.7) 4 (5.6) 61 (84.7)
Jos 0 0 0 0
Total 164 18 (11.0) 16 (9.8) 130 (79.3)
Tanzania Bagamoyo 10 2 (20.0) 0 8 (80.0)
Kiwangwa 151 23 (15.2) 14 (9.3) 114 (75.5)
Total 161 25 (15.5) 14 (8.7) 122 (75.8)
Total 1319 134 (10.2) 127 (9.6) 1058 (80.2)
Frequencies are shown as n (%).
*N is the number of patients with genotype and phenotype data.
Table 3 Relationship between phenotype and genotype
testing
G6PD genotype G6PD phenotype n/N (%)
Male A- Deficient 70/99 (70.7)
Intermediate 19/99 (19.2)
Normal 10/99 (10.1)
Male A or B Deficient 25/575 (4.3)
Intermediate 28/575 (4.9)
Normal 522/575 (90.8)
Female A-/A- Deficient 12/25 (48.0)
Intermediate 7/25 (28.0)
Normal 6/25 (24.0)
Female A-/A or A-/B** Deficient 13/174 (7.5)
Intermediate 33/174 (19.0)
Normal 128/174 (73.6)
Female AA, AB or BB Deficient 14/446 (3.1)
Intermediate 40/446 (9.0)
Normal 392/446 (87.9)
G6PD genotype: male hemizygous = A-; male normal = A or B; female
homozygous = A-/A-; female heterozygous = A/A- or B/A-; and female normal
= A/A, B/B or B/A.
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these relationships failed to reach statistical significance
overall: for genotype p = 0.134 and for phenotype p =
0.354. The difference in reinfection rate also failed to
reach statistical significance between normal and hetero-
zygous G6PD genotypes (OR 0.8; 95%CI 0.5, 1.1; p =
0.105) or normal and deficient genotypes (OR 0.8; 95%CI
0.5, 1.1; p = 0.203).
Discussion
The primary objective of this study was to describe the
prevalence of G6PD genotypes in African malaria
patients who participated in two CDA Phase III clinical
trials. In this study, G6PD*A- prevalence varied between
trial centres and between countries (Table 1). Where
comparable data exists for each country, the prevalence
of G6PD deficiency in the current study was lower com-
pared with previous reports from Burkina Faso (31.0%)
[21], and Nigeria (21.6%, 23.9% and 24.2%) [22-24], but
higher than reported for Ghana (8.5%) [25]. A study in
Mali of children with uncomplicated or complicated
malaria, reported a G6PD*A- prevalence of 12.9% [5];
about the same as reported here (10.5%). There are no
previous reports for G6PD genotype prevalence using
DNA analysis for Kenya or Tanzania for comparison.
The current study selected for particular malaria
patients, so it is not surprising that G6PD gene frequen-
cies are divergent from those reported for randomly
selected healthy individuals in the general population.
Notably, patients with known G6PD deficiency or neo-
natal hyperbilirubinaemia were excluded. Unfortunately,
data are not available on how many patients were
excluded from the clinical trials because of known
G6PD deficiency. However, anecdotally, there were
probably very few as the regions studied were naïve to
G6PD testing. Conversely, G6PD prevalence data from a
general population cannot necessarily be used to esti-
mate the proportion of G6PD-deficient individuals that
will be enrolled into an anti-malarial clinical trial. From
the postulated evolution of G6PD deficiency, it is possi-
ble that the frequency of malaria is lower in patients
with G6PD deficiency, though a protective effect against
Table 4 Baseline demographic and clinical data by G6PD genotype
Characteristic* Male
hemizygous
(n = 147)
Male
normal
(n = 871)
Female
homozygous
(n = 37)
Female
heterozygous
(n = 273)
Female
normal
(n = 717)
All patients
(n = 2045)
Age, years [range] 5.8 (8.0) [1-70] 5.1 (5.5) [1-
59]
7.9 (10.0) [1-42] 5.6 (7.8) [1-72] 5.6 (6.5) [1-
72]
5.44 (6.5) [1-72]
1- < 5, n (%) 87 (59) 511 (59) 21 (57) 169 (62) 412 (57) 1200 (59)
5- < 15, n (%) 52 (35) 331 (38) 10 (27) 90 (33) 277 (39) 760 (37)
≥ 15, n (%) 8 (5) 29 (3) 6 (16) 14 (5) 28 (4) 85 (4)
Weight, kg, mean 18.8 (11.7) 17.9 (10.5) 23.1 (21.9) 18.0 (12.2) 18.3 (11.0) 18.2 (11.3)
Parasitaemia, μL
-1, geometric mean
[range]
25990
[1484-705600]
26331
[216-
323361]
18602
[1026-211546]
22498
[0-303400]
27213
[0-389415]
25895
[0-705600]
Temperature, °C 37.8 (1.0) 37.9 (1.0) 37.9 (1.0) 37.8 (1.0) 37.9 (1.0) 37.9 (1.0)
Fever, n (%) 81 (55.1) 552 (63.4) 24 (65.0) 165 (60.0) 459 (64.0) 1281 (62.6)
Haemoglobin, g/L* 100.3 (18.3) 101.1 (16.8) 99.7 (19.2) 100.6 (14.2) 102.7 (15.6) 101.5 (16.2)
1 to < 5 years 93.2 (15.2) 95.6 (14.6) 91.0 (16.5) 96.1 (12.6) 97.3 (14.6) 96.0 (14.5)
5 to < 15 years 107.2 (15.2) 106.6 (14.8) 104.4 (12.5) 105.8 (13.2) 108.9 (13.9) 107.3 (14.3)
≥ 15 years 132.5 (16.5) 135.7 (12.2) 122.5 (17.5) 119.9 (11.9) 120.5 (9.8) 126.9 (14.0)
Haematocrit, L 0.30 (0.05) 0.30 (0.05) 0.31 (0.05) 0.31 (0.04) 0.31 (0.04) 0.31 (0.05)
RBC count x10
12/L 4.0 (0.7) 4.2 (0.6) 4.0 (0.6) 4.0 (0.5) 4.1 (0.6) 4.1 (0.62)
Platelet count x10
9/L 191.4 (86.5) 196.7
(111.6)
206.1 (125.2) 186.9 (96.4) 198.1 (128.0) 195.7 (114.5)
WBC count x10
9/L 9.6 (4.3) 9.5 (4.1) 8.5 (4.2) 9.5 (3.9) 9.4 (4.0) 9.5 (4.0)
Treatment n (%)
CDA 005 64 (43.5) 324 (37.2) 16 (43.2) 123 (45.1) 273 (38.1) 800 (39.1)
CDA 006 38 (25.9) 250 (28.7) 6 (16.2) 70 (25.6) 198 (27.6) 562 (27.5)
AL 30 (20.4) 185 (21.2) 6 (16.2) 43 (15.8) 137 (19.1) 401 (19.6)
CPG-DDS 15 (10.2) 112 (12.9) 9 (24.3) 37 (13.6) 109 (15.2) 282 (13.8)
All values are mean (SD) [range] unless otherwise indicated. CDA, chlorproguanil-dapsone-artesunate; AL, artemether-lumefantrine; CPG-DDS, chlorproguanil-
dapsone; RBC, red blood cell; WBC, white blood cell. G6PD genotype: male hemizygous = A-; male normal = A or B; female homozygous = A-/A-; female
heterozygous = A/A- or B/A-; and female normal = A/A, B/B or B/A.
*There were 23 patients with baseline haemoglobin of < 70 g/L (range 45-69 g/L, mean 65 g/L). This occurred because at some sites screening haemoglobin
level was determined using a rapid test (Haemacue, Downfield, UK), with subsequent checking using a coulter counter the results of which are reported here.
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Page 9 of 14uncomplicated malaria has not been conclusively
demonstrated.
In this study, all the G6PD*A- mutations involved
A376G/G202A, confirming this variant as the most com-
mon in Africa. The A542T, G680T or T968C G6PD*A-
mutations were not detected in the malaria patients
included in this study. Data on the frequency of these
mutations are sparse in Africa. The 968C mutation has
been reported as the most common G6PD*A- allele in
The Gambia [3] and in the Sereer ethnic group from
Senegal [8]. Given the selected population in this study it
cannot be confirmed whether any of these mutations are
not present in the countries studied. The limitations of
the assay regarding other possible G6PD-deficient muta-
tions that were not tested for in this study should also be
considered. Further genotyping studies are required to
determine the frequency of these mutations in the gen-
eral population and specific ethnic groups.
The Hardy-Weinberg equation describes a population in
which both allele and genotype frequencies do not change,
meaning they are in equilibrium. Using this equation, ten
centres had female gene frequencies significantly different
to those predicted from male gene frequencies (Table 1).
The sampling methods in the studied population (as deter-
mined by the study inclusion/exclusion criteria) may not
have enrolled the different genotypes at the same frequen-
cies that they occur in the general population. Also, the
sample size was not large enough in some centres to con-
firm or reject the hypothesis of genetic equilibrium. Other
explanations include changes in selection pressure, such as
from malaria control or anti-malarial treatment, or popula-
tion mixing. Evidence from Taiwan indicates that recent
immigration can cause changes in relative G6PD gene fre-
quencies between males and females independent of the
overall incidence of G6PD deficiency [26]. This may be
relevant for some of the centres in this study; for example,
Eldoret is one of the fastest growing towns in Kenya, and
with 250 different ethnic groups in the country, it would
be unlikely if genetic equilibrium for G6PD genotypes was
maintained. However, it is difficult to separate the complex
reasons for the divergence from Hardy-Weinberg equili-
brium and further specific investigations would be
required. There is also a methodological explanation. In
many studies on G6PD-deficiency variant prevalence, only
the frequency of the A- allele is known and this alone is
used to derive predicted female genotype frequencies for
G6PD deficient, heterozygous and normal; thus, only the
A- allele is tested for equilibrium. In this study, the fre-
quencies of the A-, A and B alleles in males were used to
calculate predicted frequencies of the female genotypes,
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Page 10 of 14A-A-, AA-, BA-, AA, BB and BA, which is a strict applica-
tion of the Hardy-Weinberg equation and so less likely to
show conformance unless all G6PD alleles and genotypes
are in equilibrium.
G6PD genotyping has limitations, for instance, it is not
practical as a routine test in a clinical setting. Also,
because the gene is highly polymorphic (more than 400
reported variants), unusual but clinically important var-
iants can be missed [2]. Phenotyping using the NADPH
fluorescence spot test is an alternative test as it detects
deficiency irrespective of underlying gene mutations
(Table 2). The biggest limitation of G6PD phenotyping is
its inability to conclusively identify heterozygous females
because their G6PD levels can range from near normal
to deficient. As shown in Table 3, 73.6% (128/174) of
female heterozygous patients were classified as ‘normal’ by
G6PD phenotyping. In the CDA trials, heterozygous
females appeared to have no greater risk for clinically
significant haemolysis than normal females (haemoglobin
decrease of ≥ 40 g/L or ≥ 40% versus baseline or haemo-
globin < 50 g/L or blood transfusion) [10,11]. However,
this cannot be assumed for all drugs.
As shown in Table 3, the specificity of phenotype test-
ing for identifying G6PD*A- was 66.1% (82/124), i.e.
33.9% (42/124) of G6PD*A- patients were not identified
by phenotype. This misclassification is probably attribu-
table to reticulocyte rebound subsequent to haemolytic
crisis, or recovery from malaria [9]. In patients with
malaria, higher than expected G6PD enzyme levels can
occur in individuals with G6PD-deficient genotypes
because the increased erythrocyte replacement rate
Table 5 Malaria recrudescence and reinfection rates at
Day 28 by G6PD genotype and phenotype
G6PD status N Recrudescence
n (%)
Reinfection
n (%)
Genotype*
Deficient 184 11 (6.0) 49 (26.6)
Heterozygous 273 11 (4.0) 71 (26.0)
Normal 1588 82 (4.0) 488 (30.7)
Total 2045 104 (5.1) 608 (29.7)
Phenotype**
Deficient 146 9 (6.2) 39 (26.7)
Intermediate 137 3 (2.2) 39 (28.5)
Normal 1096 62 (5.7) 391 (35.7)
Total 1379 74 (5.4) 469 (34.0)
*G6PD genotype: male hemizygous = A-; male normal = A or B; female
homozygous = A-/A-; female heterozygous = A/A- or B/A-; and female normal =
A/A, B/B or B/A.
**Analysis performed for patients with G6PD phenotype with or without
genotype available.
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Page 11 of 14results in a younger erythrocyte population and newly
formed erythrocytes have a greater capacity for G6PD
production [9]. However, for unknown reasons, the cor-
relation between deficient phenotype and G6PD*A- gen-
otype was better for hemizygous males, specificity 70.7%
(70/99), than for homozygous females, specificity 48.0%
(12/25). This has also been seen in a recent paper where
83.3% (30/36) of hemizygous males were phenotypically
deficient whereas specificity was only 60.0% (3/5) in
homozygous females, though numbers in the study were
very low compared with the current dataset [27]. In
males and females with normal G6PD genotype (A, B,
AA or AB), 4.3% (25/575) and 3.1% (14/446), respec-
tively, were found to be phenotypically deficient. It is
possible that these individuals might have had G6PD
mutations at loci other than those examined.
In the context of this trial, using only phenotype data
would have significantly undermined interpretation of the
drug-induced G6PD-related haemolytic effect of CDA as
about a third of G6PD*A- patients would be expected to
have had a clinically important haemolysis [10,11].
Because of this, and the limitation in identifying heterozy-
gous females, G6PD genotyping will continue to be impor-
tant, particularly in a research situation. In the wider
context, it has been suggested that phenotype could be
used to exclude G6PD*A- patients from receiving poten-
tially harmful treatments. It is possible to calculate the
number of G6PD*A- patients that would have been inad-
vertently treated after phenotype screening (Table 3).
Excluding the 134 patients who had a deficient phenotype
would leave a total population of 1185 exposed to treat-
m e n t ,4 2( 3 . 5 % )o fw h o mw e r eo fG 6 P D * A -g e n o t y p e .
Excluding patients with a deficient or intermediate pheno-
type (n = 261), leaves a total population of 1058, of whom
16 (1.5%) had a G6PD*A- genotype. The number of
G6PD*A- patients misclassified by phenotype appears
small (1.5%), i.e. about five patients would have had signifi-
cant hemolysis that would have been avoidable with geno-
typing. However, where alternative therapies exist, in the
clinical setting it would be unethical to expose even a
small proportion of patients with a G6PD-deficient geno-
type to potentially life-threatening haemolysis, particularly
where patient follow up is limited.
Across all patients, phenotype correlated reasonably well
with the occurrence of significant hemolysis. Of the 878
patients with phenotype data, significant hemolysis
occurred in 21.1% (19/90) of those patients who were phe-
notypically deficient, in 5.6% (5/90) of those who were
intermediate and in 1.1% (8/698) of those with normal
phenotype. Of the 41/124 (33.0%) G6PD*A- patients trea-
ted with CDA who had clinically important haemolysis, 23
had phenotype data available. Of these, 17/23 (73.9%)
were phenotypically deficient, 4/23 (17.4%) had intermedi-
ate phenotype and 2/23 (8.7%) had normal phenotype.
The study design excluded patients with haemoglobin
concentrations ≤ 70 g/L and this consideration may have
affected the study results. There were no independent
effects of G6PD genotype on baseline haemoglobin, tem-
perature, or malaria parasitaemia in the study population
(Table 4, Figures 2, 3 and 4). Thus, judged by these para-
meters, G6PD-deficient malaria patients appeared to be no
d i f f e r e n tf r o mo t h e rm a l a r i ap a t i e n t sa tp r e s e n t a t i o n .
T h e s er e s u l t sa r ec o n s i s t e n tw i t has t u d yi nT a n z a n i ai n
malaria patients that showed no effect of G6PD genotype
on haemoglobin concentration or parasite density [28].
Also, in Nigerian subjects with no or asymptomatic
malaria, G6PD deficiency had no significant effect on hae-
moglobin levels, though red blood cell concentrations
were higher in G6PD-normal subjects versus those who
were G6PD deficient [23].
As shown in Table 5, there was a trend for patients with
G6PD heterozygous or deficient genotypes or G6PD defi-
cient phenotype to have lower unadjusted reinfection
rates. However, after adjustment for baseline factors,
including drug treatment, no effect of G6PD genotype or
phenotype on recrudescence or reinfection rates was
found. A recent study found no effect of G6PD deficiency
on P. falciparum clearance after treatment with artemisi-
nin-based combination therapy [29]. However, there is
some evidence that G6PD deficiency may reduce the num-
ber of parasite strains carried by individuals in transmis-
sion zones/seasons [30].
There are limitations in performing post-hoc statistical
analysis on the effect of G6PD status on baseline vari-
ables and efficacy as was done in this study. Logistic
modelling also has limitations; inclusion of the variables
for adjustment is somewhat subjective and can never be
comprehensive. Therefore, the conclusions that can be
drawn from this study should be viewed as exploratory
and require verification in prospective studies.
Conclusions
The G6PD*A- deficient genotype was relatively common
among the diverse African populations included in this
study. This represents a significant risk for adverse hae-
molytic events after treatment with drug therapies that
have the potential to induce oxidative stress. G6PD geno-
typing and phenotyping should therefore be a requisite in
clinical trials evaluating the safety and efficacy of such
drugs. The G6PD prevalence data presented here are
relevant for the design of such anti-malarial clinical trials.
Lastly, there were no clinical differences between G6PD-
deficient and -normal patients with malaria enrolled into
the CDA clinical trials.
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